Skip to content

Imaging technique to predict skin death during mastectomy and reconstruction surgery

Ischaemic complications after nipple-sparing mastectomy reconstruction: Predictors and indocyanine green angiography

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12621000828820
Enrollment
274
Registered
2021-06-29
Start date
2021-07-01
Completion date
2024-07-01
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this study is to investigate whether use of an imaging technique, indocyanine green angiography (ICGA), during reconstructive breast surgery after mastectomy (removal of all breast tissue) can reduce a major complication. This complication is dead breast skin tissue (necrosis) of the overlying breast skin (mastectomy skin flap). This occurs because there is inadequate blood flow to the skin resulting in breakdown. This can result in further surgery, poor cosmetic results, delay in chemotherapy or radiotherapy, and increased costs to the healthcare system. Who is it for? You may be eligible for this study if you are aged 18 years or older, are scheduled for unilateral (one-sided) or bilateral (both sides) nipple- or skin-sparing mastectomy followed by breast reconstruction. Study details Participants will receive a mastectomy and breast reconstruction using ICGA to assess blood flow to the skin flap and make adjustments such as delay reconstruction surgery or remove dying skin. Participants will return for a follow-up assessment at 7 days, 30 days and 90 days post-surgery involving a clinical assessment of the surgical site, and will be monitored for re-admission to hospital or any other complications for 12 months post-surgery. It is hoped that this study may demonstrate that the use of intraoperative ICGA in breast reconstruction surgery following mastectomy will decrease the incidence of mastectomy skin flap necrosis compared to surgery without use ICGA, which may help to reduce complications and improve cosmetic outcome.

Interventions

Intervention: Surgery WITH Indocyanine green Angiography Materials: Laparotomy sponges and staples DRUG: Indocyanine green (ICG) supplied as a sterile water-soluble lypophilised power: Infracyanine® 25mg/10mL (SERB, Paris, France) - strength: 25mg/mL - dose: weight-dependent dosage: 2mL for patients weighing <50Kg, 3mL for patients weighing 50-100Kg, and 4mL for patients weighing over 100Kg - duration: single Stat dose - mode: intravenous injection Normal saline: 10mL flush following administra

Intervention: Surgery WITH Indocyanine green Angiography Materials: Laparotomy sponges and staples DRUG: Indocyanine green (ICG) supplied as a sterile water-soluble lypophilised power: Infracyanine® 25mg/10mL (SERB, Paris, France) - strength: 25mg/mL - dose: weight-dependent dosage: 2mL for patients weighing <50Kg, 3mL for patients weighing 50-100Kg, and 4mL for patients weighing over 100Kg - duration: single Stat dose - mode: intravenous injection Normal saline: 10mL flush following administration of indocyanine green Near-infrared light source from the SPY Elite System or SPY PHI (Novadaq Technologies Inc., Mississauga, Canada) Procedures, activities, and/or processes used: 1. Skin- or nipple-sparing mastectomy 2. Clinical assessment of mastectomy skin flap perfusion by surgeon and first assistant: skin tissue colour, capillary refill, turgor, temperature and dermal edge bleeding 3. Placement of laparotomy sponges in breast pocket to fill dead space and allow skin flaps to lie flat without areas of redundancy or stretch 4. Temporary closure of skin with staples 5. Indocyanine green administered intravenously stat, at a weight dependent dosage, just after completion of mastectomy and prior to reconstruction 6. Operating room lights will be turned off 7. Excitation of fluorescence by near-infrared light source from the fluorescence imaging systems: SPY Elite System or SPY PHI (Novadaq Technologies Inc., Mississauga, Canada) 8. Video recording of perfusion for a total of 90 seconds after fluorescence is first detected in mastectomy skin. Bilateral cases will be recorded for bilateral cases, recorded with a single administration of indocyanine green (ICG) dye and snapshots will be taken of both breasts within 10 seconds of the 90-second time point 9. Analysis of skin flap vascularisation using perfusion maps and perfusion values obtained by SPY-Q software at the 90-second-point 10. Assessment of perfusion as “well perfused”, “adequately perfused”, “marginal” or “poorly perfused” using absolute (based off of a fixed greyscale that is consistent from image to image) and relative perfusion values. 11. Surgical decision regarding reconstruction to be made such as proceeding with breast reconstruction, delaying breast reconstruction or excising nonviable tissue 12. Completion of reconstruction note: preoperative antibiotics and drains are used if indicated Who: Surgeon and first assistant Mode of delivery: Face to face, provided individually Number of times: Single dose administration of indocyanine green Duration: Angiography will video record perfusion for a total of 90 seconds after fluorescence is first detected in the mastectomy skin. Bilateral cases will be recorded with a single administration of indocyanine green (ICG) dye and snapshots will be taken of both breasts within 10 seconds of the 90-second time point. Location: Operating theatres Duration: Total duration of breast reconstruction is approximately 130minutes, with the intervention (indocyanine green administration, perfusion analyses and interpretation) adding approximately 10 minutes to the total surgical time Monitoring of adherence: Adherence to the intervention will be followed by the use of laminated sheets with instructions on dosage and administration of Indocyanine Green, and examples of well and poorly perfused skin flaps for reference.

Sponsors

Chris O’Brien Lifehouse
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

- Being scheduled for unilateral or bilateral nipple- or skin-sparing mastectomy (prophylactic or for the treatment of cancer) followed by breast construction - Participant understands the study procedures and can provide informed consent to participate in the study

Exclusion criteria

- Refusal to consent to participation in the study - Participant has known contraindication to ICG injection, i.e., previous reaction to ICG - Participant has Iodine allergy - Participant has chronic kidney disease stage 3, 4, or 5 - Participant is pregnant

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026